Variable | Proportion or central measure |
---|---|
Population demographics and health status | |
Female n (%) | 432 (57%) |
Mean age (sd) | 33.9 (7.7) |
Nationality n (%) | |
South African | 431 (57%) |
Zimbabwean | 287 (38%) |
Other African countries | 40 (5%) |
Marital status n (%) | |
Married | 174 (24%) |
Divorced or separate | 12 (2%) |
Single | 554 (75%) |
Employed n (%) | 551 (75%) |
Current alcohol use n (%) | 269 (36%) |
Current smoking n (%) | 116 (16%) |
WHO clinical stage | |
I | 433 (59%) |
II | 164 (22%) |
III | 119 (16%) |
IV | 20 (3%) |
Median CD4 cells/μL at screening (IQR), n = 755a | 208 (118-299) |
Median plasma viral load copies/mL (IQR) | 64,782 (17,646–186,662) |
Laboratory screening tests prior to antiretroviral treatment | |
Creatinine clearance n < 50 mL/min (%) | 4 (1%) |
Microalbumin-to-creatinine ratio mg/mmol n (%) | |
3.4–33.9 | 40 (5%) |
> 34.0 | 2 (0%) |
Urine dipstick n (%) | |
Proteinuria 1+ | 60 (8%) |
Proteinuria 2+ | 14 (2%) |
Proteinuria 3+ | 7 (1%) |
Hepatitis B surface antigen positive n (%) | 60 (8%) |
Abnormal ALT/AST IU/L n (%) in all patients | |
40–99 (1-2.4 X normal) | 145 (19%) |
100–199 (2.5-4.9 X normal) | 22 (3%) |
≥ 200 (≥5 X normal) | 4 (1%) |
Abnormal ALT/AST IU/L n (%) If hepatitis B positive | |
40–99 | 19 (32%) |
100–199 | 2 (3%) |
≥ 200 | 2 (3%) |
Anaemia in females n (%) | |
8–10.0 g/dL | 40 (9%) |
< 8.0 g/dL | 10 (2%) |
Anaemia in males n (%) | |
8–10.0 g/dL | 13 (4%) |
< 8.0 g/dL | 2 (1%) |
Neutrophil count | |
< 0.75 × 10^9 /L n (%) | 7 (1%) |
Median cells (IQR) | 2.2 (1.6-2.9) |
Platelet counts (cells/μl) n (%) | |
< 50,000 | 3 (0) |
50,000--125,000 | 25 (3) |